Post-earnings recap
Reported
Thu, May 8, 2014
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report shows that Alnylam Pharmaceuticals had a strong EPS performance, exceeding expectations significantly. However, the stock reacted negatively, declining by 2.62%. This decline may reflect investor concerns over the lack of revenue data and guidance, which can create uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.39 | N/A | +133.05% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a sense of cautious optimism regarding the company's future prospects. They highlighted the positive EPS surprise as a sign of solid underlying performance.
Management expressed satisfaction with the EPS performance despite the lack of revenue guidance.
They emphasized ongoing efforts in research and development to drive future growth.